Medifast Q2 2025: Revenue Drops 37.4% but Net Income Shows Signs of Recovery Amid Challenges

Medifast, Inc. (NYSE: MED) - Q2 2025 Overview

Medifast, Inc. continues to face challenges reflected in its recent income statement for Q2 2025. Below are key points highlighting both positive and negative aspects of the company's financial performance:

Key Financial Highlights:

• Revenue: For the three months ended June 30, 2025, revenue dropped to $105.6 million from $168.6 million in Q2 2024, representing a 37.4% decline.
• Gross Profit: Gross profit decreased by 37.9% to $76.6 million, with the gross margin slightly reducing from 73.2% to 72.6%.
• Net Income: Medifast reported a net income of $2.5 million, an improvement compared to a net loss of $8.2 million in Q2 2024, indicating a substantial turnaround.
• Earnings per Share: Earnings per share were $0.22 (diluted) for Q2 2025 compared to a loss of $0.75 per share in Q2 2024.
• Cost of Sales: Costs fell from $45.1 million to $28.9 million (down 35.9%), aligning with the revenue decrease.
• SG&A Expenses: Selling, general and administrative expenses significantly dropped, totaling $77.7 million in Q2 2025, down from $131.3 million in Q2 2024, primarily driven by reductions in OPTAVIA coach compensation.
• Active Coaches: The number of active OPTAVIA coaches declined to 22,800, a 32.7% decrease year-over-year, impacting overall revenue growth.
• Other Income: Other income showed a significant improvement, totaling $3.9 million instead of a prior loss, largely thanks to gains on investments.
• Cash Position: Cash and cash equivalents increased from $90.9 million at the end of 2024 to $101.7 million by June 30, 2025.

Negative Aspects:

• Despite net income growth, total revenue is on a declining trend, with substantial drops compared to the previous year.
• Client acquisition challenges continue to weigh heavily, resulting in fewer active coaches and affecting sales volumes.
• The average revenue per active coach decreased to $4,630, reflecting sustained pressure in the operating environment.
• Overall loss from operations was reported at $1.1 million, although that was an improvement compared to the year-ago period.

Conclusion: Medifast, Inc. (NYSE: MED) is navigating a turbulent market landscape with a noticeable decline in revenue due to reduced active coaches and broader economic pressures. Positive signs of improved net income and reduced costs present a mixed outlook as the company strives to improve its client acquisition strategies and product offerings to adapt to evolving consumer needs.